Omeros (OMER) Trading Down 6.1%
Omeros Co. (NASDAQ:OMER) shares dropped 6.1% during mid-day trading on Friday . The company traded as low as $15.14 and last traded at $15.19. Approximately 541,857 shares were traded during mid-day trading, a decline of 22% from the average daily volume of 693,416 shares. The stock had previously closed at $16.17.
OMER has been the subject of a number of analyst reports. Zacks Investment Research downgraded Omeros from a “buy” rating to a “hold” rating in a report on Wednesday, October 25th. Wedbush restated an “outperform” rating and issued a $47.00 price objective on shares of Omeros in a research report on Tuesday, November 28th. Maxim Group set a $24.00 price objective on Omeros and gave the company a “buy” rating in a research report on Friday, October 20th. HC Wainwright set a $30.00 price objective on Omeros and gave the company a “buy” rating in a research report on Thursday, January 4th. Finally, Cowen cut Omeros from an “outperform” rating to a “market perform” rating in a research report on Thursday, November 2nd. Five equities research analysts have rated the stock with a hold rating, five have issued a buy rating and one has assigned a strong buy rating to the company’s stock. The stock presently has an average rating of “Buy” and a consensus price target of $34.14.
The firm has a market capitalization of $729.18, a PE ratio of -11.78 and a beta of 3.30. The company has a debt-to-equity ratio of 8.99, a quick ratio of 4.74 and a current ratio of 4.77.
Several institutional investors have recently bought and sold shares of OMER. C M Bidwell & Associates Ltd. purchased a new stake in shares of Omeros in the fourth quarter valued at approximately $106,000. First Interstate Bank purchased a new stake in shares of Omeros during the third quarter worth approximately $108,000. Legal & General Group Plc increased its position in shares of Omeros by 7.8% during the second quarter. Legal & General Group Plc now owns 10,359 shares of the biopharmaceutical company’s stock worth $208,000 after purchasing an additional 751 shares in the last quarter. Hanseatic Management Services Inc. increased its position in shares of Omeros by 10,919.6% during the third quarter. Hanseatic Management Services Inc. now owns 10,689 shares of the biopharmaceutical company’s stock worth $231,000 after purchasing an additional 10,592 shares in the last quarter. Finally, Malaga Cove Capital LLC purchased a new stake in shares of Omeros during the fourth quarter worth approximately $242,000. Institutional investors and hedge funds own 50.26% of the company’s stock.
Omeros Corporation is a biopharmaceutical company. The Company is engaged in discovering, developing and commercializing small-molecule and protein therapeutics for large-market, as well as orphan indications targeting inflammation, coagulopathies and disorders of the central nervous system. Its marketed drug product, Omidria (phenylephrine and ketorolac injection), is used during cataract surgery or intraocular lens (IOL) replacement.
Receive News & Ratings for Omeros Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Omeros and related companies with MarketBeat.com's FREE daily email newsletter.